-- Scott Roberts
TUESDAY, July 16 (HealthDay News) -- The first medical device
designed to help medical professionals diagnose attention
deficit/hyperactivity disorder (ADHD) in children and teens has
been approved by the U.S. Food and Drug Administration.
The Neuropsychiatric EEG-Based Assessment Aid (NEBA) records and
analyzes electric impulses produced by the brain's nerve cells, the
agency said in a news release. The non-invasive device, which takes
about 20 minutes to produce complete results, measures brain wave
frequencies called theta and beta waves. The theta/beta ratio has
been shown to be higher in young people with ADHD, the FDA
Citing the American Psychiatric Association, the FDA said about
9 percent of U.S. adolescents have ADHD, and the average age of
diagnosis is 7 years. Children with ADHD typically have behavior
problems, trouble paying attention and hyperactivity.
Device maker NEBA Health submitted data from a clinical study of
275 children and adolescents, ranging in age from 6 to 17. The
study found that the new device helped professionals better
diagnose children with ADHD when combined with a psychological
assessment, compared to a psychological assessment alone.
NEBA is based in Augusta, Ga.
The U.S. Centers for Disease Control and Prevention has more
EBSCO Information Services is fully accredited by URAC. URAC is an independent, nonprofit health care accrediting organization dedicated to promoting health care quality through accreditation, certification and commendation.
Please be aware that this information is provided to supplement the care provided by your physician. It is neither intended nor implied to be a substitute for professional medical advice. CALL YOUR HEALTHCARE PROVIDER IMMEDIATELY IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY. Always seek the advice of your physician or other qualified health provider prior to starting any new treatment or with any questions you may have regarding a medical condition.
Copyright © EBSCO Information Services. All rights reserved.